CEMI - Chembio Diagnostics: COVID-19 Test Is A Game-Changer But Stock Remains Speculative
U.S. based Chembio Diagnostics, Inc. (NASDAQ:CEMI) develops and manufactures point-of-care diagnostic tests that detect infectious diseases. While the company's core products in recent years were related to HIV and other viral diseases, Chembio shifted its focus this year towards the COVID-19 pandemic. In March, the company announced it had developed a rapid blood test which gave the stock some new bullish momentum. Shares are up over 430% over the period further supported by news of an FDA approval and strong market demand. The company reported its latest quarterly results which included an update